Cyclo Therapeutics Inc. (NASDAQ: CYTH)
$1.23
+0.0250 ( +2.08% ) 49.7K
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Market Data
Open
$1.23
Previous close
$1.20
Volume
49.7K
Market cap
$34.91M
Day range
$1.20 - $1.26
52 week range
$0.89 - $2.12
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Oct 31, 2023 |
4 | Insider transactions | 1 | Oct 23, 2023 |
4 | Insider transactions | 1 | Oct 23, 2023 |
4 | Insider transactions | 1 | Oct 23, 2023 |
4 | Insider transactions | 1 | Oct 23, 2023 |
4 | Insider transactions | 1 | Oct 23, 2023 |
8-k | 8K-related | 15 | Oct 20, 2023 |
8-k | 8K-related | 13 | Sep 27, 2023 |
8-k | 8K-related | 17 | Sep 21, 2023 |
4 | Insider transactions | 1 | Aug 22, 2023 |